

SENESCO TECHNOLOGIES INC  
Form 8-K  
July 25, 2007

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d) OF THE**  
**SECURITIES EXCHANGE ACT OF 1934**

Date of report (Date of earliest event reported): **July 23, 2007**

**Senesco Technologies, Inc.**

(Exact Name of Registrant as Specified in Charter)

**Delaware**  
(State or Other Jurisdiction  
of Incorporation)

**001-31326**  
(Commission File Number)

**84-1368850**  
(IRS Employer  
Identification No.)

**303 George Street,**  
**Suite 420,**  
**New Brunswick, New Jersey**  
(Address of Principal Executive Offices)

**08901**  
(Zip Code)

**(732) 296-8400**

(Registrant's telephone number, including area code)

**Not applicable**

## Edgar Filing: SENESCO TECHNOLOGIES INC - Form 8-K

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
  - o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).
  - o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).
  - o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).
-

**Item 1.01 Entry into a Material Definitive Agreement.**

On July 23, 2007, Senesco Technologies, Inc. (the Company ) entered into a License Agreement (the Agreement ) with Bayer CropScience AG ( Bayer ) under which Bayer will exclusively license the rights to the Company s proprietary gene technology for global use in cotton, to be used in Bayer s FiberMax® brand. The financial terms of the Agreement are structured such that the Company will receive payments for the achievement of certain success-bound development milestones, as well as commercialization royalties. In addition, the Agreement provides that the Company shall also receive a fully-paid up, royalty-free, non-exclusive license to any improvements made on the gene technology by Bayer, with the exception of improvements relating to cotton and other specifically enumerated crops. The Agreement shall remain in full force and effect until the last of the patents underlying the Agreement expires or until the licensed know-how underlying the Agreement becomes part of the public domain, whichever is later. The Agreement may also be terminated by Bayer or the Company upon thirty (30) days written notice.

A copy of the Agreement will be filed as an exhibit to the Company s annual report on Form 10-K. On July 24, 2007, the Company issued a press release announcing the Agreement.

**Item 9.01. Financial Statements and Exhibits.**

**(d) Exhibits.**

Exhibit

No.	Description
99.1	Press Release of Senesco Technologies, Inc. dated July 24, 2007.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

**SENESCO TECHNOLOGIES, INC.**

Dated: July 25, 2007

By: /s/ Bruce Galton  
Name: Bruce Galton  
Title: President and Chief Executive Officer